Health Zymeworks Halts Development of ZW171 for Cancer Treatment The clinical development of the mesothelin-directed T-cell engager ZW171 for treating patients with gynecological, thoracic, and gastrointestinal (GI) cancers has been discontinued, as announced... Editorial16 hours ago